PMID- 10495778
OWN - NLM
STAT- MEDLINE
DCOM- 19991014
LR  - 20171116
IS  - 0041-008X (Print)
IS  - 0041-008X (Linking)
VI  - 159
IP  - 2
DP  - 1999 Sep 1
TI  - Selective modulation of B-cell activation markers CD86 and I-Ak on murine 
      draining lymph node cells following allergen or irritant treatment.
PG  - 142-51
AB  - It is well known that T cells are key effector cells in the development of 
      allergic contact dermatitis. However, we and others have shown that mice exposed 
      to contact allergens show a preferential increase in B lymphocytes in the 
      draining lymph nodes (DLN) as seen by an increase in the percentage of B220+ or 
      IgG/IgM+ cells. The purpose of the present investigation was to determine whether 
      chemical allergens, in contrast to irritants, would modulate B-cell activation 
      markers, CD86 and I-Ak, on B cells isolated from DLN of treated mice using the 
      local lymph node assay (LLNA) protocol. Mice were treated on the ears for 3 
      consecutive days with concentrations of allergens (1-chloro-2,4-dinitrobenzene, 
      alpha-hexylcinnamaldehyde, 4-ethoxymethylene-2-phenyl-2-oxazoline-5-one, and 
      trinitrochlorobenzene), or irritants (benzalkonium chloride and sodium lauryl 
      sulfate), which caused an increase in the number of DLN cells. The DLN were 
      excised 72 h following the final chemical treatment, and the cells were prepared 
      for analysis by flow cytometry. In mice treated with allergens an increase in the 
      median intensity of I-AK and CD86 on B220+ or IgG/IgM+ B cells was observed 
      compared to mice treated with irritants or vehicles. Mice treated with allergens 
      demonstrated an increase in the median intensity of CD86 on B220+ B cells that 
      was dose dependent and peaked at 72 h following the final allergen treatment. The 
      increase in the median intensity of I-AK also was dose dependent but peaked at 96 
      h. Finally, T and B cells isolated from both allergen- and irritant-treated mice 
      demonstrated an increase in [3H]thymidine incorporation compared to 
      vehicle-treated and naive mice at 72 h following the final chemical treatment. 
      The results suggest that B cells isolated from DLN of allergen-treated mice are 
      activated and proliferating. Analysis of B-cell activation markers may be useful 
      in differentiating allergen and irritant responses in the draining lymph nodes of 
      chemically treated mice.
FAU - Gerberick, G F
AU  - Gerberick GF
AD  - Miami Valley Laboratories, Procter & Gamble Company, Cincinnati, Ohio 45253-8707, 
      USA.
FAU - Cruse, L W
AU  - Cruse LW
FAU - Miller, C M
AU  - Miller CM
FAU - Ridder, G M
AU  - Ridder GM
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - Toxicol Appl Pharmacol
JT  - Toxicology and applied pharmacology
JID - 0416575
RN  - 0 (Allergens)
RN  - 0 (Antibodies)
RN  - 0 (Antigens, CD)
RN  - 0 (B7-2 Antigen)
RN  - 0 (Biomarkers)
RN  - 0 (Cd86 protein, mouse)
RN  - 0 (Histocompatibility Antigens Class II)
RN  - 0 (I-Ak antigen)
RN  - 0 (Immunoglobulin G)
RN  - 0 (Immunoglobulin M)
RN  - 0 (Immunoglobulins)
RN  - 0 (Irritants)
RN  - 0 (Membrane Glycoproteins)
SB  - IM
MH  - Allergens/*immunology/pharmacology
MH  - Animals
MH  - Antibodies
MH  - Antigens, CD/*analysis
MH  - B-Lymphocytes/*drug effects
MH  - B7-2 Antigen
MH  - Biomarkers
MH  - Dose-Response Relationship, Drug
MH  - Ear, External/drug effects
MH  - Female
MH  - Flow Cytometry
MH  - Histocompatibility Antigens Class II/*analysis
MH  - Immunoglobulin G/metabolism
MH  - Immunoglobulin M/metabolism
MH  - Immunoglobulins/*metabolism
MH  - Irritants/*immunology/pharmacology
MH  - Lymph Nodes/*drug effects
MH  - *Lymphocyte Activation
MH  - Membrane Glycoproteins/*analysis
MH  - Mice
MH  - Mice, Inbred CBA
MH  - T-Lymphocytes/drug effects
MH  - Time Factors
EDAT- 1999/09/25 00:00
MHDA- 1999/09/25 00:01
CRDT- 1999/09/25 00:00
PHST- 1999/09/25 00:00 [pubmed]
PHST- 1999/09/25 00:01 [medline]
PHST- 1999/09/25 00:00 [entrez]
AID - S0041-008X(99)98734-3 [pii]
AID - 10.1006/taap.1999.8734 [doi]
PST - ppublish
SO  - Toxicol Appl Pharmacol. 1999 Sep 1;159(2):142-51. doi: 10.1006/taap.1999.8734.